Journal
NATURE COMMUNICATIONS
Volume 9, Issue -, Pages -Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41467-018-07644-6
Keywords
-
Categories
Funding
- NIH [R35 CA197731-01, R50CA211447]
- Chemical Biology Core Facility at the H. Lee Moffitt Cancer Center & Research Institute
- SAIL Core Facility at the H. Lee Moffitt Cancer Center & Research Institute
- NCI-designated Comprehensive Cancer Center [P30-CA076292]
- Molecular Genomics Core Facility at the H. Lee Moffitt Cancer Center & Research Institute
Ask authors/readers for more resources
Mutant KRas is a significant driver of human oncogenesis and confers resistance to therapy, underscoring the need to develop approaches that disable mutant KRas-driven tumors. Because targeting KRas directly has proven difficult, identifying vulnerabilities specific for mutant KRas tumors is an important alternative approach. Here we show that glycogen synthase kinase 3 (GSK3) is required for the in vitro and in vivo growth and survival of human mutant KRas-dependent tumors but is dispensable for mutant KRas-independent tumors. Further, inhibiting phosphorylation of GSK3 substrates c-Myc on T58 and beta-catenin on S33/S37/141 and their subsequent upregulation contribute to the antitumor activity of GSK3 inhibition. Importantly, GSK3 blockade inhibits the in vivo growth of G12D, G12V, and G12C mutant KRas primary and metastatic patient-derived xenografts from pancreatic cancer patients who progressed on chemo- and radiation therapies. This discovery opens new avenues to target mutant KRas-dependent cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available